State of New Jersey Common Pension Fund D Has $926,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX

State of New Jersey Common Pension Fund D decreased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 61.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,686 shares of the biopharmaceutical company’s stock after selling 63,770 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Catalyst Pharmaceuticals were worth $926,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jones Financial Companies Lllp increased its position in shares of Catalyst Pharmaceuticals by 14.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 498 shares during the last quarter. Navellier & Associates Inc. grew its stake in shares of Catalyst Pharmaceuticals by 6.6% in the third quarter. Navellier & Associates Inc. now owns 13,346 shares of the biopharmaceutical company’s stock valued at $263,000 after buying an additional 822 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in Catalyst Pharmaceuticals by 8.9% during the second quarter. E Fund Management Co. Ltd. now owns 10,656 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 871 shares during the last quarter. Juncture Wealth Strategies LLC increased its holdings in Catalyst Pharmaceuticals by 1.1% during the fourth quarter. Juncture Wealth Strategies LLC now owns 84,342 shares of the biopharmaceutical company’s stock worth $1,969,000 after buying an additional 940 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Catalyst Pharmaceuticals by 1.0% during the second quarter. California State Teachers Retirement System now owns 99,257 shares of the biopharmaceutical company’s stock worth $2,154,000 after acquiring an additional 992 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

CPRX opened at $31.15 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The company has a 50-day simple moving average of $25.56 and a 200 day simple moving average of $24.07. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 18.43, a P/E/G ratio of 0.95 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CPRX shares. Truist Financial raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Oppenheimer downgraded Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Finally, Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.17.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).